SCHEMBL26136263

SCHEMBL26136263

COc1cc2c(-c3ccc(NC(=O)C4(c5ccc(F)cc5)CC4)cc3)ncnc2cc1OCC1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 8/20 0.48
▸ EGFR P00533 6/20 0.48
▸ FGFR1 P11362 5/20 0.48
▸ FLT1 P17948 5/20 0.48
▸ FLT4 P35916 5/20 0.48
▸ MET P08581 5/20 0.47
▸ KIT P10721 4/20 0.47
▸ RAF1 P04049 1/20 0.46
▸ AXL P30530 3/20 0.45
▸ TYRO3 Q06418 2/20 0.45
▸ MERTK Q12866 2/20 0.45
▸ PDGFRB P09619 2/20 0.44
▸ EPHA2 P29317 2/20 0.44
▸ AURKA O14965 2/20 0.43
▸ RIPK2 O43353 1/20 0.43
▸ ABCB11 O95342 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ ERBB2 P04626 1/20 0.43
▸ NTRK1 P04629 1/20 0.43
▸ LCK P06239 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30394178 0.91 KDR (0.48) KDREGFRFGFR1FLT1FLT4
SCHEMBL26535219 0.89 KIT (0.50) KDREGFRMETKITPDGFRB
SCHEMBL29238247 0.87 KIT (0.50) KDREGFRFGFR1FLT1FLT4
SCHEMBL26099698 0.85 KDR (0.47) KDREGFRFGFR1FLT1FLT4
SCHEMBL26101038 0.84 RAF1 (0.48) KDREGFRFGFR1FLT1FLT4
SCHEMBL26101262 0.84 KDR (0.51) KDREGFRFGFR1FLT1FLT4
SCHEMBL26536043 0.81 KDR (0.46) KDREGFRFGFR1FLT1FLT4
SCHEMBL30891790 0.81 KDR (0.46) KDREGFRFGFR1FLT1FLT4
SCHEMBL26102350 0.81 KDR (0.46) KDREGFRFGFR1FLT1FLT4
SCHEMBL30394312 0.80 KDR (0.47) KDREGFRFGFR1FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB KDR 5/4885EGFR 79/4885FGFR1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback